Curing What Ails Alzheimer’s Drug Development
Biomarkers will be key to winning the race to a successful AD drug. Even then, drugmakers must build the infrastructure for getting therapy to the right patients at the right time.
You may also be interested in...
Despite high-profile failures, including the recent disappointing results for Axovant Science’s Phase III MINDSET study, the trial landscape for Alzheimer’s disease remains busy.
The Dementia Discovery Fund won a $50m private investment from Bill Gates – plus his ringing support to probe beyond the amyloid beta hypothesis in hopes of eventually defeating Alzheimer's.
A new trial for CNP520 will see if the Amgen/Novartis BACE1 inhibitor can prevent, stop or slow Alzheimer's disease progression in pre-symptomatic patients, but recruiting enough patients with the APOE4 gene will require a massive screening effort.